Since the primary function of CYP1-3 enzymes is facilitating drug metabolism, the main concern of the dysregulation of CYP expression in COVID-19 is the direct impact on drug disposition and pharmacokinetics in humans. This evidence concerns the gene PPIG and COVID-19.